ADMA Biologics Inc (ADMA)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 103,147 | 51,352 | 86,522 | 51,089 | 55,921 |
| Short-term investments | US$ in thousands | — | — | — | — | — |
| Receivables | US$ in thousands | 49,999 | 27,421 | 15,505 | 28,577 | 13,237 |
| Total current liabilities | US$ in thousands | 55,542 | 49,806 | 39,267 | 30,378 | 19,947 |
| Quick ratio | 2.76 | 1.58 | 2.60 | 2.62 | 3.47 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($103,147K
+ $—K
+ $49,999K)
÷ $55,542K
= 2.76
The quick ratio of ADMA Biologics Inc has demonstrated some fluctuations over the past five years. As of December 31, 2020, the quick ratio stood at a healthy 3.47, indicating a strong ability to cover its short-term liabilities with its most liquid assets. However, there was a slight decrease in the quick ratio by the end of December 2021 to 2.62. Despite this decrease, the company still maintained a comfortable liquidity position.
In the following years, the quick ratio continued to hover around the 2.6 range, with a value of 2.60 as of December 31, 2022, and 2.76 as of December 31, 2024. These figures suggest that ADMA Biologics Inc remained capable of meeting its short-term obligations using its quick assets.
Notably, there was a significant drop in the quick ratio to 1.58 by December 31, 2023. This decrease may indicate a potential strain on the company's liquidity position during that period.
Overall, ADMA Biologics Inc's quick ratio has shown some variability over the years, with fluctuations possibly reflecting changes in its liquidity management or operational efficiency. Investors and analysts may need to monitor the company's quick ratio closely to assess its short-term liquidity health accurately.
Peer comparison
Dec 31, 2024